Alexion Pharmaceuticals, Inc. (ALXN) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Alexion Pharmaceuticals, Inc. (ALXN)

ALXN 182.50

0.0%

Jul 28 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Larry Liebman who started this subject	11/3/2003 12:56:43 PM
From: Ian@SI	of 824

Monday, November 10, 2003 3:00 p.m. Eastern To participate in this call, dial: 913-981-5509 confirmation code: 232605 shortly before 3:00 p.m. Eastern The web cast can be accessed at: alexionpharm.com . A replay of the call will be available for a limited period following the call, beginning at 6:00 p.m., Eastern. The replay number is 719-457-0820, confirmation code 232605. As previously announced, results of the Phase III PRIMO-CABG clinical trial will be presented at the American Heart Association Scientific Meeting, at the Plenary Session III: Late-Breaking Clinical Trials #2, on November 10th at the Orange County Convention Center, Orlando, at 10:45 a.m. Eastern. The presentation will be made by Dr. Edward D. Verrier, William K. Edmark Professor and Chief of Cardiovascular Surgery at the University of Washington, and the Chairman of the PRIMO-CABG Steering Committee.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next